A Conformationally Constrained Peptidomimetic Binds to the Extracellular Region of HER2 Protein

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Biomolecular Structure and Dynamics

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/07391102.2010.10507360PMID 20919746PMCID PMC3005560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VPAC1 receptor binding site: contribution of photoaffinity labeling approach.

  2010cited by this paper
• Structure-Based and Ligand-Based Drug Design for HER 2 Receptor

  2010cited by this paper
• An Insight to the Dynamics of Conserved Water Molecular Triad in IMPDH II (Human): Recognition of Cofactor and Substrate to Catalytic Arg 322

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Computer-aided Drug Design of Novel PLA2 Inhibitor Candidates for Treatment of Snakebite

  2009cited by this paper
• Sequence Analysis, Structure Prediction, and Functional Validation of phaC1/phaC2 Genes of Pseudomonas sp. LDC-25 and Its Importance in Polyhydroxyalkanoate Accumulation

  2009cited by this paper
• ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor

  2009cited by this paper
• Molecular Dynamics Simulations to Gain Insights into the Stability and Morphologies of K3 Oligomers from β2-microglobulin

  2009cited by this paper
• Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques

  2009cited by this paper
• Weighted Equation and Rules—A Novel Concept for Evaluating Protein-Ligand Interaction

  2009cited by this paper
• Conformational Dynamics of Human AP Endonuclease in Base Excision and Nucleotide Incision Repair Pathways

  2009cited by this paper
• Molecular Dynamics Simulations to Investigate the Structural Stability and Aggregation Behavior of the GGVVIA Oligomers Derived from Amyloid β Peptide

  2009cited by this paper
• Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2–Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell lines

  2009cited by this paper
• Immunophilins and HIV-1 V3 Loop For Structure-Based Anti-AIDS Drug Design

  2009cited by this paper
• Molecular Modeling Studies of the Interaction Between Plasmodium falciparum HslU and HslV Subunits

  2009cited by this paper
• Molecular dynamics simulations to gain insights into the stability and morphologies of K3 oligomers from beta2-microglobulin.

  2009cited by this paper
• Disruption Mechanism in the Helix of SPF Peptide by Interchanging E5 and K10 Residues: Inference from Molecular Dynamics Study

  2009cited by this paper
• Ligand-Based Dual Target Drug Design for H1N1: Swine Flu- A Preliminary First Study

  2009cited by this paper
• Conserved Water Mediated H-bonding Dynamics of Inhibitor, Cofactor, Asp 364 and Asn 303 in Human IMPDH II

  2009cited by this paper
• Molecular Dynamics Simulations to Investigate the Aggregation Behaviors of the Aß(17–42) Oligomers

  2009cited by this paper
• Molecular dynamics simulations to investigate the structural stability and aggregation behavior of the GGVVIA oligomers derived from amyloid beta peptide.

  2009cited by this paper
• Structure-based view of epidermal growth factor receptor regulation.

  2008cited by this paper
• Molecular Modeling and Characterization of the B. thuriiigiensis and B. thuringiensis LDC-9 Cytolytic Proteins

  2008cited by this paper
• Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs.

  2008cited by this paper
• Study of Early Events in the Protein Folding of Villin Headpiece using Molecular Dynamics Simulation

  2008cited by this paper
• Computational Anti-AIDS Drug Design Based on the Analysis of the Specific Interactions Between Immunophilins and the HIV-1 gp120 V3 Loop. Application to the FK506-Binding Protein

  2008cited by this paper
• What is the Effective Component in Suanzaoren Decoction for Curing Insomnia? Discovery by Virtual Screening and Molecular Dynamic Simulation

  2008cited by this paper
• Binding Properties of the C‐terminal Domain of VIAF

  2008cited by this paper
• ZRANK: Reranking protein docking predictions with an optimized energy function

  2007cited by this paper
• A semiempirical free energy force field with charge‐based desolvation

  2007cited by this paper
• Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo1

  2007cited by this paper
• Building blocks

  2007cited by this paper
• MolProbity: all-atom contacts and structure validation for proteins and nucleic acids

  2007cited by this paper
• Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities*

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• New dual inhibitors of EGFR and HER2 protein tyrosine kinases.

  2005cited by this paper
• HER1/EGFR targeting: refining the strategy.

  2004cited by this paper
• Molecular approach to breast cancer treatment.

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase

  2004cited by this paper
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

  2004cited by this paper
• Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.

  2003cited by this paper
• Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation

  2003cited by this paper
• An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

  2003cited by this paper
• HER-2-targeted therapy: lessons learned and future directions.

  2003cited by this paper
• Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

  2003cited by this paper
• EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

  2003cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Biologic and therapeutic role of HER2 in cancer

  2003cited by this paper
• ZDOCK: An initial‐stage protein‐docking algorithm

  2003cited by this paper
• Molecular targets in breast cancer: current status and future directions.

  2002cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.

  2002cited by this paper
• Double Naphthalene‐Tagged Cyclodextrin‐Peptide Capable of Exhibiting Guest‐Induced Naphthalene Excimer Fluorescence

  2002cited by this paper
• Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics*

  2002cited by this paper
• Anti‐human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

  2001cited by this paper
• Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

  2001cited by this paper
• Mutagenesis Reveals a Role for Epidermal Growth Factor Receptor Extracellular Subdomain IV in Ligand Binding*

  1999cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Induced circular dichroism spectra of α-, β-, and γ-cyclodextrin complexes with π-conjugate compounds. Part 2. Chiral dimer formation and polarization directions of the π–π* transitions in some hydroxyazo guests having a naphthalene nucleus†

  1999cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Circular Dichroism and the Conformational Analysis of Biomolecules

  1996cited by this paper
• NMRPipe: A multidimensional spectral processing system based on UNIX pipes

  1995cited by this paper
• Structure determination from NMR data II: computational approaches

  1993cited by this paper
• NMR evidence of a short linear peptide that folds into a .beta.-hairpin in aqueous solution

  1993cited by this paper
• The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity.

  1993cited by this paper
• NMR of proteins and nucleic acids

  1988cited by this paper
• Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

  1988cited by this paper
• Structure elucidation of longikaurin A and longikaurin B, new biologically active diterpenoids from Rabdosia longituba and chemical conversion of oridonin into dihydrolongikaurin A

  1988cited by this paper
• Practical aspects of two-dimensional transverse NOE spectroscopy

  1985cited by this paper
• MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy

  1985cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Improved spectral resolution in cosy 1H NMR spectra of proteins via double quantum filtering.

  1983cited by this paper
• Buildup rates of the nuclear Overhauser effect measured by two-dimensional proton magnetic resonance spectroscopy: implications for studies of protein conformation

  1981cited by this paper
• An in vitro microassay for lymphotoxin using microculture plates and the multiple automated sample harvester.

  1974cited by this paper

• The Dual Role of Nanomaterials in Ovarian Cancer and Female Fertility as Anti- and Prooxidants

  2025cites this paper
• Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics

  2023cites this paper
• Peptidomimetics in cancer targeting

  2022cites this paper
• Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy

  2021cites this paper
• In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC

  2020cites this paper
• Computationally-guided design and affinity improvement of a protein binder targeting a specific site on HER2

  2020cites this paper
• Dynamical Rearrangement of Human Epidermal Growth Factor Receptor 2 upon Antibody Binding: Effects on the Dimerization

  2019cites this paper
• DISPOT: a simple knowledge-based protein domain interaction statistical potential

  2019cites this paper
• Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

  2018cites this paper
• Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.

  2018cites this paper
• A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization

  2017cites this paper
• Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2.

  2016cites this paper
• Structural Basis and Mechanism of Chiral Benzedrine Molecules Interacting With Third Dopamine Receptor.

  2016cites this paper
• Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.

  2016cites this paper
• Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.

  2015cites this paper
• Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2‐Positive Breast Cancer

  2015cites this paper
• Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin

  2015cites this paper
• Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors

  2015cites this paper
• Improved Peptide-Targeted Liposome Design Through Optimized Peptide Hydrophilicity, Ethylene Glycol Linker Length, and Peptide Density.

  2015cites this paper
• Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.

  2014cites this paper
• Subangstrom Accuracy in pHLA-I Modeling by Rosetta FlexPepDock Refinement Protocol

  2014cites this paper
• Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.

  2013cites this paper
• Inhibition of mushroom tyrosinase by a newly synthesized ligand: inhibition kinetics and computational simulations

  2012cites this paper
• Inhibition of protein–protein interaction of HER2–EGFR and HER2–HER3 by a rationally designed peptidomimetic

  2012influential citation
• Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile

  2012cites this paper
• Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.

  2011cites this paper
• Biological Evaluation and Interaction of a Newly Designed Anti-cancer Pd(II) Complex and Human Serum Albumin

  2011cites this paper
• Modeling of Transition State by Molecular Dynamics. Prediction of Catalytic Efficiency of the Mutants of Mandelate Racemase

  2011cites this paper
• Pharmacophore Modeling and Hybrid Virtual Screening for the Discovery of Novel IκB Kinase 2 (IKK2) Inhibitors

  2011cites this paper
• Biphasic Association of T7 RNA Polymerase and a Nucleotide Analogue, Cibacron Blue as a Model to Understand the Role of Initiating Nucleotide in the Mechanism of Enzyme Action

  2011cites this paper
• Screening from the World's Largest TCM Database Against H1N1 Virus

  2011cites this paper
• Compounds of the 1,5-di(4-R-phenyl)-3-selenopentanediones-1,5 series interaction with the Basidiomycete Lentinula edodes, lectins: Computations and Experiment

  2011cites this paper
• Molecular Modeling of Mycobacterium Tuberculosis dUTpase: Docking and Catalytic Mechanism Studies

  2011cites this paper
• Structure and Stability Analysis of Cytotoxic Complex of Camel α-Lactalbumin and Unsaturated Fatty Acids Produced at High Temperature

  2011cites this paper
• The Key Residues of Active Sites on the Catalytic Fragment for Paclitaxel Interacting with Poly (ADP-Ribose) Polymerase

  2011cites this paper
• Docking Studies on the Binding of Quinoline Derivatives and Hematin to Plasmodium Falciparum Lactate Dehydrogenase

  2011cites this paper
• Molecular Dynamics and Docking Studies on Cardiac Troponin C

  2011cites this paper
• Comparison of Binding Interactions of Lomefloxacin to Serum Albumin and Serum Transferrin by Resonance Light Scattering and Fluorescence Quenching Methods

  2011cites this paper
• Insight into the Inhibitory Mechanism and Binding Mode Between D77 and HIV-1 Integrase by Molecular Modeling Methods

  2011cites this paper
• BetaDock: Shape-Priority Docking Method Based on Beta-Complex

  2011cites this paper